Recent Updates
Recently added Catalysts

CPERT

Phase 1

Thyroid Neoplasms | Small molecule | Oncology |Avalon GloboCare Corp.|Last Updated: Nov 14, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

ACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

CPERT · 1 trial · 1 indication

Phase 1 1
NCT01437254To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid CancerThyroid Neoplasms
COMPLETED30 Analytics
PHASE1COMPLETED
To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer
Thyroid NeoplasmsUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety of CPERT
7 months

CPERT safety will be assessed by evaluation of vital signs (pre-injection and post-imaging), blood haematology (pre-injection and post-imaging), SMA-12 clinical biochemistry profile (pre-injection and post-imaging) and collection of adverse events.

Secondary Endpoints

Comparison of general biodistribution of CPERT and GPERT.
7 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
Arm Number 1 CPERTEXPERIMENTAL1 CPERT scan, blood and vital sign collection
Arm Number 2 GPERTACTIVE_COMPARATOR1 GPERT Scan

Interventions

NameTypeDescription
CPERTDRUGSingle 340 MBq CPERT scan in first 10 subjects
GPERTDRUGSingle 340 MBq GPERT scan in up to 20 case-matched controls
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 79 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * If female of child-bearing potential and outside of the window of 10 days since the first day of the last menstrual period, a negative pregnancy test is required. * Have confirmed well differentiated thyroid cancer, post-thyroidectomy and pre-RAI * Biochemical parameters as me...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about CPERT

What is CPERT used for?

CPERT is an investigational small molecule being studied for use in thyroid neoplasms, which are tumors of the thyroid gland. It is currently in Phase 1 clinical development as a diagnostic or imaging agent for this condition.

Who makes CPERT?

CPERT is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company's stock is traded under the ticker symbol ALBT.

What phase is CPERT in?

CPERT is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.

What clinical trials is CPERT in?

CPERT has one completed clinical trial, identified as NCT01437254. This Phase 1 study compared the safety and imaging patterns of cyclotron-produced technetium versus generator-produced technetium in patients with thyroid cancer. The trial enrolled 30 participants in Canada.

How does CPERT work?

CPERT is a small molecule that contains technetium, a radioactive element used in medical imaging. It is designed to be used as an imaging agent to visualize thyroid tissue or tumors, helping to assess thyroid neoplasms.